Molecular structure of Moexipril hydrochloride, CAS Number: 82586-52-5
Moexipril hydrochloride (CAS 82586-52-5)
Application:
Moexipril hydrochloride is an angiotensin-converting enzyme (ACE) inhibitor
CAS Number:
82586-52-5
Purity:
≥99%
Molecular Weight:
535.03
Molecular Formula:
C27H34N2O7•HCl
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Moexipril hydrochloride is a potent inhibitor to the ACE (angiotensin converting enzyme), blocking the conversion of angiotensin I to angiotensin II. Moexipril in addition, has cardioprotective effects mediated through a combination of angiotensin II inhibition and bradykinin proliferation. The proliferation of bradykinin stimulates the production of prostaglandin E2 and nitric oxide.
Moexipril hydrochloride (CAS 82586-52-5) References
- Simultaneous determination of moexipril hydrochloride and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods. | Ertürk, S., et al. 2003. J Pharm Biomed Anal. 33: 505-11. PMID: 14550868
- The influence of relative humidity and temperature on stability of moexipril hydrochloride in solid phase. | Stanisz, B. 2004. Acta Pol Pharm. 61: 91-6. PMID: 15493289
- Moexipril and left ventricular hypertrophy. | Chrysant, GS. and Nguyen, PK. 2007. Vasc Health Risk Manag. 3: 23-30. PMID: 17583172
- Determination of antihypertensive drug moexipril hydrochloride based on the enhancement effect of sodium dodecyl sulfate at carbon paste electrode. | Attia, AK. 2010. Talanta. 81: 25-9. PMID: 20188882
- Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations. | Stanisz, B., et al. 2013. Drug Dev Ind Pharm. 39: 51-61. PMID: 22348774
- First order derivative spectrophotometric and HPLC methods for determination of moexipril hydrochloride in the pure form, pharmeceutical formulations and evaluation of its stability. | Stanisz, B., et al. 2012. Acta Pol Pharm. 69: 389-95. PMID: 22594252
- Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation. | Gu, L., et al. 1990. Pharm Res. 7: 379-83. PMID: 2362911
- Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. | Friehe, H. and Ney, P. 1997. Arzneimittelforschung. 47: 132-44. PMID: 9079232
- Preclinical safety studies of the combination moexipril hydrochloride/hydrochlorothiazide. | Gietl, R., et al. 1998. Arzneimittelforschung. 48: 365-70. PMID: 9608878
Inhibitor of:
ACE, and Protease.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Moexipril hydrochloride, 10 mg | sc-204095 | 10 mg | $135.00 | |||
Moexipril hydrochloride, 50 mg | sc-204095A | 50 mg | $575.00 |